AzTrials
AzTrials

Research institution

Ottawa Heart Institute Research Corporation Clinical Trials

Studies where Ottawa Heart Institute Research Corporation is the lead sponsor: what is enrolling now, by phase, condition and country.

182 registered studies

In numbers

Open to volunteers
42
Active
61
With results posted
20
All registered
182

Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.

Open to volunteers

All 42
  • Mitral Regurgitation, Mitral Valve Disease

    LEFT ATRIAL MONITORING IN PATIENTS BEFORE AND AFTER MITRAL SURGERY - LAMBDA STUDY

    • Recruiting
    • Age: 18 years and older

    Mitral valve leakage, or mitral regurgitation (MR), is associated with heart failure symptoms including shortness of breath, fatigue, irregular heart rate. When left untreated, it may cause death.

    Conditions
    Mitral Regurgitation, Mitral Valve Disease, Heart Failure
    Trial name
    LAMBDA (NCT06547788)
    Testing
    Mitral valve repair with creation of an 8 mm inter-atrial shunt
    Where
    Canada
    Volunteers
    50 people
    Sponsor
    Ottawa Heart Institute Research Corporation
    Can I take part? LAMBDA
  • Cardiac Sarcoidosis

    Cardiac Sarcoidosis Multi-Center Prospective Cohort

    • Recruiting
    • Age: 18 to 99 years
    • Observational study

    Recent data has shown that sarcoidosis, presenting initially with cardiac manifestations (CS) of either conduction system disease or cardiomyopathy and sustained VT, is not uncommon.

    Trial name
    CHASM-CS (NCT01477359)
    Where
    14 sites in Canada, Japan
    Volunteers
    1,500 people
    Sponsor
    Ottawa Heart Institute Research Corporation
    Can I take part? CHASM-CS
  • Nicotine Dependence, Cigarettes, Nicotine Withdrawal

    The INITIATE Study: Initiating Nicotine Dependence Treatment for Smokers Admitted to Emergency Departments

    • Recruiting
    • Age: 18 years and older
    • Lifestyle or therapy programme

    The INITIATE Study is a randomized controlled trial that is testing an intervention designed to increase long-term abstinence among tobacco smokers seen in emergency departments (ED) and other high-volume hospital and community…

    Trial name
    INITIATE (NCT04163081)
    Testing
    Quit Card Intervention (QCI)
    Where
    4 sites in Canada
    Volunteers
    1,208 people
    Sponsor
    Ottawa Heart Institute Research Corporation
    Can I take part? INITIATE
  • Ablation Techniques, Atrial Fibrillation (Paroxysmal)

    Paroxysmal Atrial Fibrillation Repeat Ablation Strategies With Durably Isolated Pulmonary Veins

    • Not yet recruiting
    • Age: 18 years and older
    • Surgery or procedure

    This study looks at participants who have undergone an ablation procedure for atrial fibrillation previously, and atrial fibrillation has occurred and a second ablation procedure is needed.

    Conditions
    Ablation Techniques, Atrial Fibrillation (Paroxysmal), Quality of Life
    Trial name
    PARADISO (NCT07910825)
    Testing
    Tailored Strategy, Control Strategy
    Where
    Canada
    Volunteers
    60 people
    Sponsor
    Ottawa Heart Institute Research Corporation
    Can I take part? PARADISO
  • High Risk Bleeding

    Investigating a Personalized Approach to Anti-Platelet Therapy

    • Not yet recruiting
    • Age: 18 years and older
    • Phase 4

    RAPID PREVENT aims to identify if a personalized (targeted) anti-platelet strategy will reduce bleeding events when compared to the current standard anti-platelet therapy.

    Trial name
    RAPID PREVENT (NCT07602257)
    Testing
    Genotyping guided therapy for anti-platelet management
    Where
    Canada
    Volunteers
    1,760 people
    Sponsor
    Ottawa Heart Institute Research Corporation
  • Pericarditis

    Pericardial Imaging Study

    • Recruiting
    • Age: 18 years and older
    • Phase 3

    The pericardium is a thin, double-layered sac around the heart that helps reduce friction as the heart moves. When this sac gets inflamed, it is called pericarditis, which can cause serious health problems and even be…

    Trial name
    NCT07245849
    Testing
    18F-FDG PET/CT
    Where
    Canada
    Volunteers
    44 people
    Sponsor
    Ottawa Heart Institute Research Corporation
  • Menopause, Sleep Disruption

    Endocrine Disruption, Menopause, and Poor Sleep in wOmen With Type 2 Diabetes: Effects on Cardiovascular Health

    • Not yet recruiting
    • Age: 48 to 58 years
    • Observational study

    EMPOWER aims to determine the overall effect of menopause and sleep disruption on cardiac remodeling in women with type 2 diabetes.

    Conditions
    Menopause, Sleep Disruption, T2DM
    Trial name
    EMPOWER (NCT07486986)
    Testing
    4 years of clinical evaluations.
    Volunteers
    381 people
    Sponsor
    Ottawa Heart Institute Research Corporation
    Can I take part? EMPOWER
  • Ascending Aortic Aneurysm Enlargement, Ascending Aorta Aneurysm

    Treatment in Thoracic Aortic Aneurysm: Surgery vs Surveillance

    • Recruiting
    • Age: 18 to 79 years
    • Surgery or procedure

    The ascending aorta conducts blood from the heart to the rest of the body. The ascending aorta can become enlarged, and the risk of tearing and rupturing becomes higher with larger aorta.

    Trial name
    TITAN:SvS (NCT03536312)
    Testing
    Thoracic Aortic Surgery
    Where
    31 sites in United States, Canada and 1 more
    Volunteers
    610 people
    Sponsor
    Ottawa Heart Institute Research Corporation
    Can I take part? TITAN:SvS
  • Hypervolemia, Cardiogenic Shock

    Capital Offload-Shock

    • Not yet recruiting
    • Age: 18 years and older
    • Phase 4

    CAPITAL OFFLOAD-SHOCK will aim to answer if early use of renal replacement therapy, like dialysis, in patients with reduced body fluids causing the heart to be unable to pump enough blood through the body reduces in-hospital…

    Conditions
    Hypervolemia, Cardiogenic Shock, Renal Replacement Therapies
    Trial name
    OFFLOAD-SHOCK (NCT07756801)
    Testing
    Immediate renal replacement therapy
    Where
    Canada
    Volunteers
    456 people
    Sponsor
    Ottawa Heart Institute Research Corporation
  • COVID - 19, Long COVID Syndrome

    Dapagliflozin for Long COVID Syndrome

    • Not yet recruiting
    • Age: 18 years and older
    • Phase 3

    This is a randomized, placebo-controlled study. Patients with long COVID will be randomized to receive dapagliflozin or placebo for 12 months.

    Conditions
    COVID - 19, Long COVID Syndrome, SARS CoV-2
    Trial name
    DALCO (NCT06907251)
    Testing
    Dapagliflozin (DAPA)
    Where
    Canada
    Volunteers
    192 people
    Sponsor
    Ottawa Heart Institute Research Corporation
    Can I take part? DALCO

Completed, with results posted

All 19

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in